Tag Archives: travel

FREE Pre-RESI Event: Structuring Your Startup: Legal, Tax, Funding, and Strategic Decisions

3 Sep

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation (LSN) invites early-stage life science and healthcare companies to a free, in-person pre-conference event designed to equip founders and executives with the knowledge and tools to build a successful venture in the U.S. market.

Structuring Your Startup: Legal, Tax, Funding, and Other Strategic Decisions will be held on Tuesday, September 16, from 1:00–5:00 PM at CIC Cambridge, Havana Room, One Broadway, Cambridge, MA. Taking place the day before RESI Boston 2025 (September 17–19), this workshop is a valuable opportunity for companies in town for Biotech Week Boston to gain practical insights and make new connections.

Attendees will hear from leading organizations, including Polsinelli, Eva Garland, LabCentral, Savills, and EisnerAmper, along with LSN, on the critical decisions that shape an emerging life science company. Topics will span legal frameworks, risk mitigation, tax considerations, fundraising approaches, deal structuring, operational planning, and pathways for life science companies entering or looking to scale within the U.S. market.

The program also features time dedicated to networking, giving founders and executives the chance to connect with peers, advisors, and potential partners before the RESI conference begins.

This pre-conference session is part of LSN’s ongoing effort to support life science entrepreneurs in landing their companies in the Boston innovation ecosystem and expanding into the U.S. market.

Registration is free, but space is limited. Don’t miss your chance to join.

Tags: , , , , , , , , , , , ,

Innovator’s Pitch Challenge Applications Now Open for RESI London and RESI JPM

26 Aug

Showcase your innovation to active life science investors

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation (LSN) is now accepting applications for the Innovator’s Pitch Challenge (IPC) at both RESI London and RESI JPM. The IPC provides early-stage life science and healthcare companies with the opportunity to pitch directly to a panel of active investors, receive interactive feedback, and showcase their technology in the RESI Exhibition Hall.

RESI London – December 2025

The first week of December marks the largest life science partnering and venture week in the UK. For companies raising pre-seed through Series B, or those in Phase II or earlier development, RESI London—alongside One Nucleus’ Genesis and ELRIG/SLAS events—offers a stronger fit compared to the late November healthcare week held concurrently with Jefferies. While Jefferies tends to focus on IPO-ready or Phase III+ companies, RESI London is designed for venture-stage entrepreneurs seeking investment and strategic partnerships.

The conference takes place in person on December 4 at No.11 Cavendish Square, London, with virtual partnering continuing on December 8–9.

Apply to Pitch at RESI London >>

Application Deadline: Friday, October 24

RESI JPM – January 2026

The RESI Conference will return to San Francisco during JP Morgan Healthcare Week, providing entrepreneurs with access to the largest gathering of early-stage life science investors in the world. Taking place January 12–13 at the Marriott Marquis San Francisco, the conference will be followed by three days of virtual partnering on January 14, 19, and 20.

RESI JPM draws more than a thousand participants, including 500+ global investors, innovators, and industry experts. The Innovator’s Pitch Challenge allows selected companies to pitch live, engage in Q&A with investors, and participate in dedicated partnering meetings throughout the week.

Apply to Pitch at RESI JPM >>

Application Deadline: Wednesday, November 12

Apply today to secure your place in the Innovator’s Pitch Challenge at RESI London or RESI JPM and take advantage of the opportunity to showcase your innovation directly to active investors.

Tags: , , , , , , , , , , , ,

Pullan’s Pieces #4 – January – A Corner on Market Sentiments – Seed to Series A

19 Aug

As the saying goes, “What’s in a name?  That which we call a Series A by any other name would smell as sweet.”  Er… something like that, right? Hmmm, maybe it went a little bit differently.

But whatever it be, or not to be😊, the Seed Round is the new Series A. Clearly. I think we’ve all felt it for sometime but the data is in and the good ‘ole Series A just don’t buy what it used to.  Nahhh… the Seed round does that, and it may buy more (equity) than it used to as a Series A (more data hunting and crunching required but one gets a sense that the venture capitalists are, well, capitalizing).

Labiotech does a really nice job collecting and summarizing a variety of topics related to financings and dealmaking in the biotech sector and the 2024 breakdown of funding offers the following approximations (roughly, with some rounding made by this author):

The internal breakdowns for amounts invested look like this:

Readers of this corner will know that we keep a close eye on the XBI

As usual, the outliers can skew the numbers (more on this in a moment) but the median amounts invested into these rounds puh-rihhhty much drive the nail in the coffin of the old thinking about Series dynamics. This data could be charted in another way in which an inverted bell curve would appear and a GAPING hole between $20M and $50M would stare back at you.  Think about that for a moment… if you can’t get to value inflection for ~$15-20M, you better be raising $60-75M and have multiple reasons to do so as a cursory view of the companies listed in the dataset further indicates that the lower outliers (sub-median) on the Series A were generally geared for “finding out” about a single asset in the clinic.

Back to that previously mentioned outlier that can skew the averages… it also happens to bring even more of a spotlight to those famed words from Shakespeare which began this Corner on Market Sentiments.  One of the companies in the 2024 data set raised a whopping $100,000,000 … as a Seed Round!!  Indeed, a rose by any other name…

Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Advancing Early-Stage Drug Discovery with Mosaic Biosciences

12 Aug

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiLife Science Nation is featuring Mosaic Biosciences, a returning RESI Boston sponsor dedicated to advancing early-stage drug discovery. Led by Chief Executive and Scientific Officer, Eric Furfine, Mosaic partners with biotech innovators to turn promising concepts into clinical candidates. In this interview, Eric shares how Mosaic’s experience and collaborative approach set them apart in moving ideas toward the clinic, and the types of partners they’re hoping to meet at RESI Boston.

Watch the interview:

Interested in RESI Sponsorship & Exhibitor Opportunities

Whether you’re looking for face-to-face meetings, premium visibility, or lead-generation tools, we offer customized packages designed to support your goals.

Contact Us to Customize Your Sponsorship

Tags: , , , , , , , ,

Partnering Launches August 11 for RESI Boston September 

5 Aug

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Partnering at RESI Boston 2025 is set to launch next Monday, August 11. The RESI series have consistently been the largest early-stage life science partnering events, in terms of investor attendance, and with 400+ investors/ strategic licensing partners expected to participate in September, RESI Boston September will be a turnkey event for entrepreneurs who are looking to raise capital.

With both in person and virtual registration options, as well as a handful of remaining spots open in our Innovator’s Pitch Challenge, companies can take advantage of Life Science Nation (LSN)’s unique partnering system to set meetings directly with global investors/ in-licensors who are a fit for their product’s sector, indication, stage of development and geographic region.

Companies looking to register can do so before this Friday, August 8th to take advantage of our Early Bird Pricing discounts. LSN will also be hosting a free partnering tutorial webinar on August 18th to help companies maximize the number of secured meetings.

Tags: , , , , , , , , , , ,

Pullan’s Pieces #4 – China, Japan, Europe, Korea vs US- Collaborate or Compete?

5 Aug

As a deal maker, where should I go for a deal?  Where is my competition?

There is so much written about China, I thought I would try to put it in the context of other countries.

DEMOGRAPHICS:  China is Big but low GDP per capita, Japan has the oldest population.  Both Japan and China may have reached peak population, while the US has immigration to continue growth.  China and Japan have more big cities (making clinical trial recruitment easier).

The Medical Culture varies tremendously.  

The US, with the 3rd largest population and private insurance, has the biggest market

But there are even bigger differences in the magnitude of sales of new drugs. In the US, to be in the top 10 in 2031 means double digit billions.

The biggest company R&D budgets per company are in “Global companies”.

The biggest European and Japanese companies have become global companies. 

The biggest companies in the US have 45%-70% of their Rx sales in the US.

The biggest companies in Europe have 15%-30% of their Rx sales in Europe.

The biggest companies in Japan have <10% (Takeda) to 39% of their sales in Japan. (Smaller Japanese companies have most of their Rx sales in Japan)

The biggest Chinese companies have 80-95% of their sales in China.

2024 saw a surge in approvals: In 2024, China first-approved 93 innovative drugs, with 42% being domestically developed. But China is losing domestic market share to MNCs.

The biggest Korean companies with biologics (Samsung and Celltrion) have 10-20% of their sales in Korea.  The other big Korean companies have 70-90% of their Rx sales in Korea.

But China has almost as many drugs in Phase 1 thru 3 as the US, in almost as many companies as in the US.  

There are more companies getting series A in the US and in China but the dollar amount is smaller in China. 

The US leads in IPOs

But the Hong Kong Hang Seng Biotech Index was up 87% year to date (while the US XBI was down 6%).  

Europe is active in company acquisitions, but Asia is not.  

For companies with headquarters in the US, Europe, Japan and Korea:  most partnering deals are early and with more in-licensing than out-licensing. 

China does more out-licensing than in-licensing.  

So as a deal-maker, what do I think this data suggests?

1)  You need to capture value from the US, the biggest market and home of blockbusters.

2) US companies do the most in-licensing. US and Europe do the most M&A.

3) The most deals in 2024 and 1st Half of 2025 are still done at discovery and preclinical.

4) Japanese companies are increasingly global companies and do more in-licensing than out-licensing.

5)  China is a source of drugs to bring in, with many drugs in the pipeline and new series A companies needing partners to maximize their value. China does more out-licensing than in-licensing.  Presumably, the huge China vs China competition is pushing Chinese companies to innovate more to compete and to do deals.   And more exits (IPOs and M&A) encourages more VC funding of innovation.

6)  But the low cost and the high populations cities (for fast recruitment) means China should be considered for collaborations for your drug development.  (Just remember you need 20% of patients in the US for FDA approval).

7) Korea is a high-income market but small.  In-licensing deals are often early or at market stage.

Tags: , , , , , , , , , , , , , , , , , , ,

MantaBio: RESI Boston Pitch Challenge Winner Shares What’s Next 

22 Jul

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiMantaBio earned third place in the Innovator’s Pitch Challenge (IPC) at RESI Boston this past June, standing out among a competitive field of early-stage life science companies. In this interview, Co-Founder and President Carter Boisfontaine shares insights into the company’s fundraising efforts, their experience at RESI, and what’s ahead for the team.

Watch the interview:

Interested in pitching your company at RESI?

Applications are now open for the Innovator’s Pitch Challenge at RESI Boston, September 17, 2025. Selected companies receive full access to the conference, partnering meetings with investors, and exhibit space in the RESI Exhibition Hall. New! The September 2025 IPC Pitch Package now includes an optional second RESI pass at no additional cost, allowing an additional team member to attend and participate in partnering. Apply now!

Apply to Pitch at RESI Boston Sept. 2025

Tags: , , , , , , , ,

← Older Entries
Newer Entries →